Earlier this month, more than 45,000 oncology stakeholders convened at the American Society of Clinical Oncology (ASCO) congress in Chicago to share, learn, and debate the latest cutting-ed
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials.
ADCs are designed to deliver chemotherapy directly to tumours. However, more than 95% of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity.